Human immunoglobulin is produced from human plasma, which is a sterile solution. Human immunoglobulin (IGIV) is administered intravenously to treat primary immunodeficiency. Human immunoglobulin also aids individuals with immune thrombocytopenic purpura in obtaining more platelets (cells that aid in blood clotting) and those with B-cell chronic lymphocytic leukemia in avoiding infections. People with Kawasaki disease are administered human immunoglobulin to prevent aneurysms caused by weak heart arteries. Intravenous human immunoglobulin (pH4) is also being studied to treat COVID-19. The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is expected to develop due to this. As the frequency of disease epidemics increases, so does the need for increasingly sophisticated detection methods. Consequently, it is anticipated that the market for human immunoglobulin (pH4) for intravenous injection (COVID-19) will expand, just as it did in the aftermath of the COVID-19 coronavirus illness outbreak. In the future years, the licensing of intravenous human immunoglobulin products by regulatory bodies is anticipated to contribute to the expansion of the market for human immunoglobulin (pH4) for intravenous injection (COVID-19).
During the period from 2020 to 2027, the market for Human Immunoglobulin Ph4 For Intravenous Injection (COVID-19) is projected to grow at a CAGR of 12.7%.
Major Players in the Human Immunoglobulin Ph4 for Intravenous injection Industry
1. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, was founded in 1781 and headquartered in Tokyo, Japan. It operates in approximately 80 countries. Takeda announced in April 2023 that the U.S. Food and Drug Administration (FDA) had approved a supplemental biologics license application (sBLA) for expanding the use of HYQVIA to treat primary immunodeficiency (PI) in children aged 2 to 16 years. HYQVIA is the only subcutaneous immune globulin (ScIG) infusion that can be administered monthly – every three or four weeks – and was first approved in the United States in 2014 for the treatment of PI in adults.
2. Baxter International Inc.
Baxter International Inc. is an American multinational healthcare company, was founded in 1931 and headquartered in Deerfield, Illinois. It operates in more than 100 countries. In Jan 2023,
3. Bayer AG
Bayer AG was founded in 1863 and headquartered in North Rhine-Westphalia, Germany. It operates in 83 countries.
4. CSL Behring
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. It was founded in 1904 and headquartered in Pennsylvania. It operates in more than 100 countries. In April 2023, the U.S. Food and Drug Administration (FDA) has approved a 50mL/10gm prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid), according to the global leader in biotechnology CSL Behring. Individuals with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) can now choose from an extensive selection of prefilled syringe sizes made available by CSL Behring. Hizentra is the first and only immune globulin (Ig) available in a prefilled syringe that is uncomplicated, convenient, and ready to use.
5. Grifols S.A
Grifols S.A is a Spanish multinational pharmaceutical and chemical manufacturer, was founded in 1940 and headquartered in Barcelona, Spain. It operates in more than 30 countries. In April 2022, Grifols S.A. has completed the acquisition of Biotest, an important and transformative transaction that will stimulate development and innovation. The acquisition of Biotest AG by Grifols enables the company to accelerate and expand its product line, increase patient access to plasma medicines, administer the largest private network of plasma facilities in Europe (87 sites), and drive revenue growth and margin expansion.
6. Octapharma AG
Octapharma AG is a family-owned pharmaceutical company, was founded in 1983 and headquartered in Lachen, Switzerland. It operates in 118 countries. In June 2023, immune globulin (human) is currently in Phase III of clinical development by Octapharma for Obsessive-Compulsive Disorder.
7. Shanghai RAAS Blood Products Co., Ltd.
Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and headquartered in Shanghai, China. It operates in nearly 20 countries.
8. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. was founded in 1985 and headquartered in Sichuan, China. It operates in about 100 countries across Asia.
9. ADMA Biologics, Inc.
ADMA Biologics, Inc. was founded in 2004 and headquartered in Ramsey, New Jersey. It operates in Europe and selected countries in North Africa and the Middle East. In Dec 2022, the United States Food and Drug Administration ("FDA") has approved ADMA Biologics, Inc.'s supplemental Biologics License Applications (BLAs) for ASCENIV and BIVIGAM to include room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life. ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to producing, marketing, and developing specialty plasma-derived biologics. All current and future lots of ASCENIV and BIVIGAM in the commercial supply chain are covered by the room temperature authorization.
10. Sinopharm Group Co., Ltd.
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company, was founded in 1998 and headquartered in Shanghai, China. It operates in more than 120 countries. In Sept 2021, Sinopharm develops two mild Covid-19 treatments.The medications are formulated with convalescent plasma-derived human immunoglobulin and monoclonal antibody.
Definition: Immunoglobulins (Ig) from humans are made from big pools of whole blood or plasma from apheresis. Immunoglobulins or antibodies are essential in protecting against bacteria, viruses, and fungi. When there is a deficiency of these glycoproteins, recurrent infectious diseases occur,
